![AbbVie-sign](https://pharmaphorum.com/wp-content/uploads/2016/05/AbbVie-sign.jpg)
AbbVie preps filings after ABBV-951 tops oral Parkinson's dr...
AbbVie has reported that a subcutaneous infusion of Parkinson's disease candidate ABBV-951 was more effective than standard oral therapy in a phase 3 trial, paving the way for regulatory fi